Insilico studies of 2-methylheptyl isonicotinate produced by Streptomyces sps. 201 against dihydrodipicolinate synthase enzyme of Mycobacterium tuberculosis

Abstract

Tuberculosis is thought to have infected one-third of the world’s population and antibiotic resistance is a growing problem in multi-drug-resistant tuberculosis which is caused by Mycobacterium tuberculosis (MTB). It has been reported that Mycobacterial cell walls are characterized by high DAP (diaminopimelic acid) content—an intermediate of the (S)-lysine biosynthetic pathway. Hence, the Lysine/DAP biosynthetic pathway is a promising target because of its role in cell wall and amino acid biosynthesis. In this study we performed a molecular docking analysis of a novel antibacterial isolated from Streptomyces sps. 201 against dihydrodipicolinate synthase (DHDPS) enzyme of Mycobacterium tuberculosis. The docking studies suggest that the novel molecule binds at active site LYS 171 forming a cleft and at other potential ligand binding site exhibiting all the major interactions such as hydrogen bonding, hydrophobic interaction and electrostatic interaction with (THR55, TYR143, ARG148, LYS171, VAL257 and GLY256) residues.

Share and Cite:

Pradeep Singh, S. , Lochan Bezbaruah, R. and Chandra Bora, T. (2012) Insilico studies of 2-methylheptyl isonicotinate produced by Streptomyces sps. 201 against dihydrodipicolinate synthase enzyme of Mycobacterium tuberculosis. Journal of Biophysical Chemistry, 3, 233-237. doi: 10.4236/jbpc.2012.33027.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Kumar, V., Abbas, A.K., Fausto, N. and Mitchell, R.N. (2007) Robbins basic pathology (8th Edtion). Saunders Elsevier, 516-522.
[2] Jasmer, R.M., Nahid, P., Hopewell P.C. (2002) Clinical practice. Latent tuberculosis infection. The New England Journal of Medicine, 347, 1860-1866. doi:10.1056/NEJMcp021045
[3] World Health Organization (2007) Tuberculosis. http://who.int/mediacentre/factsheets/fs104/en/index.html
[4] World Health Organization (2009) Global tuberculosis control: epidemiology, strategy, financing. Epidemiology, 6-33. http://who.int/entity/tb/publications/global_report/2009/pdf/chapter1.pdf
[5] Kefala, G., Evans, G.L., Griffin, M.D., Devenish, S.R., Pearce, F.G., Perugini, M.A., Gerrard J.A., Weiss, M.S. and Dobson, R.C. (2008) Crystal structure and kinetic study of dihydrodipicolinate synthase from Mycobacterium tuberculosis. Biochemical Journal, 411, 351-360. doi:10.1042/BJ20071360
[6] Turner, J.J., Gerrard, J.A. and Hutton, C.A. (2005) Heterocyclic inhibitors of dihydrodipicolinate synthase are not competitive. Bioorganic & Medicinal Chemistry, 13, 2133-2140. doi:10.1016/j.bmc.2005.01.001
[7] Turner, J.J., Healy, J.P., Dobson, R.C., Gerrard, J.A. and Hutton, C.A. (2005) Two new irreversible inhibitors of dihydrodipicolinate synthase: diethyl(E,E)-4-oxo-2,5-heptadiene-dioate and diethyl(E)-4-oxo-2-heptenedioate. Bioorganic & Medicinal Chemistry, 15, 995-998. doi:10.1016/j.bmcl.2004.12.043
[8] Turner, J.J., Gerrard, J.A. and Hutton, C.A. (2005) Conformationally constrained diketopimelic acid analogues as inhibitors of dihydrodipicolinate synthase. Bioorganic & Medicinal Chemistry, 13, 2133-2140. doi:10.1016/j.bmc.2005.01.001
[9] Bordoloi, G.N., Babita, K., Arijit, G., Manobjyoti, B., Yadav, R.N.S., Manoj, K.R. and Bora, T.C. (2001) Isolation and structure elucidation of a new antifungal and antibacterial antibiotic produced by Streptomycin sp. 201. Bioscience, Biotechnology, and Biochemistry, 65, 1856-1858.
[10] Bordoloi, G., Kumari, B., Bordoloi, M., Roy, M.K. and Bora, T.C. (2001) A process for the production of 2-methyl-heptyl isonicotinate. Indian Patent NF-9/2000.
[11] Bordoloi, G., Kumari, B., Bordoloi, M., Roy, M.K. and Bora, T.C. (2000) 2-Methylheptyl isonicotinate as novel antibiotic. Indian Patent NF-116/2001.
[12] Bordoloi, G., Kumari, B., Bordoloi, M., Roy, M.K., Bora, T.C. (2000) A process for the production of 2-methylheptyl isonicotinate. US Patent 009 NF 2000, 10/027913.
[13] Molegro APS: MVD 5.0 Molegro Virtual Docker, DK-8000 Aarhus C, Denmark.
[14] Aarti, G., Rupinder, T. and Gajendra, P.S.R. (2010) Virtual screening of potential drug-like inhibitors against Lysine/DAP pathway of Mycobacterium tuberculosis. BMC Bioinformatics, 11, S53.
[15] CambridgeSoft Corporation: Chemoffice (2008) USA.
[16] Ulrich B. and Allinger, N. L. (1982) Molecular mechanics. Journal of the American Chemical Society.
[17] Lipinski, C.A., Lombardo, F., Dominy B.W. and Feeney P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3-25. doi:10.1016/S0169-409X(96)00423-1
[18] Filimonov, D.A. and Poroikov, V.V., PASS Computerized prediction of biological activity spectra for chemical substances, Bioactive compound design: Possibilities for industrial use. BIOS Scientific Publishers, Oxford, 47-56.
[19] Thomsen, R. and Christensen, M.H. (2006) MolDock: A new technique for high-accuracy molecular docking. Journal of Medicinal Chemistry, 49, 3315-3321. doi:10.1021/jm051197e
[20] Storn, R. and Price, K. (1995) Differential evolution—A simple and efficient adaptive scheme for global optimization over continuous spaces. International Computer Science Institute, Berkley.
[21] Gehlhaar, D.K., Verkhivker, G., Rejto, P.A., Fogel, D.B., Fogel, L.J. and Freer, S.T. (1995) Docking conformationally flexible small molecules into a protein binding site through evolutionary programming. Proceedings of the Fourth International Conference on Evolutionary Programming, Morgan Kaufmann, San Mateo, 615-627.
[22] Gehlhaar, D. K., Bouzida, D. and Rejto, P.A. (1998) Fully automated and rapid flexible docking of inhibitors covalently bound to serine proteases. Proceedings of the Seventh International Conference on Evolutionary Programming, Morgan Kaufmann, San Mateo, 449-461.
[23] Yang, J.M. and Chen, C.C. (2004) Gemdock: A generic evolutionary method for molecular docking. Proteins, 55, 288-304. doi:10.1002/prot.20035

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.